Impact of Obesity on Biochemical Control After Radical Prostatectomy for Clinically Localized Prostate Cancer: A Report by the Shared Equal Access Regional Cancer Hospital Database Study Group

2004 ◽  
Vol 22 (3) ◽  
pp. 446-453 ◽  
Author(s):  
Stephen J. Freedland ◽  
William J. Aronson ◽  
Christopher J. Kane ◽  
Joseph C. Presti ◽  
Christopher L. Amling ◽  
...  

Purpose Given the limited information regarding the impact of obesity on treatment outcomes for prostate cancer, we sought to examine the relationship between body mass index (BMI) and cancer control after radical prostatectomy (RP). Patients and Methods We compared clinicopathologic and biochemical outcome information across BMI groups from 1,106 men treated with RP between 1988 and 2002. Multivariate analysis was used to determine if BMI significantly predicted adverse pathology or biochemical recurrence. Results Obesity was related to year of surgery (P < .001) and race (P < .001), with black men having the highest obesity rates. Obese patients had higher biopsy and pathologic grade tumors (P < .001). On multivariate analysis, BMI ≥ 35 kg/m2 was associated with a trend for higher rates of positive surgical margins (P = .008). Overweight patients (BMI, 25 to 30 kg/m2) had a significantly decreased risk of seminal vesicle invasion (P = .039). After controlling for all preoperative clinical variables including year of surgery, BMI ≥ 35 kg/m2 significantly predicted biochemical failure after RP (P = .002). After controlling for surgical margin status, BMI ≥ 35 kg/m2 remained a significant predictor of biochemical failure (P = .012). There was a trend for BMI ≥ 35 kg/m2 to be associated with higher failure rates than BMI between 30 and 35 kg/m2 (P = .053). Conclusion The percentage of obese men undergoing RP in our data set doubled in the last 10 years. Obesity was associated with higher-grade tumors, a trend toward increased risk of positive surgical margins, and higher biochemical failure rates among men treated with RP. A BMI ≥ 35 kg/m2 was associated with a higher risk of failure than a BMI between 30 and 35 kg/m2.

2015 ◽  
Vol 2 (2) ◽  
Author(s):  
Bahram Mofid ◽  
Ali Kakroodi ◽  
Nasser Simforoosh ◽  
Afshin Rakhsha ◽  
Ahmad R. Mafi

2019 ◽  
Vol 50 (1) ◽  
pp. 66-72 ◽  
Author(s):  
Hideki Enokida ◽  
Yasutoshi Yamada ◽  
Shuichi Tatarano ◽  
Hirofumi Yoshino ◽  
Masaya Yonemori ◽  
...  

Abstract Background Patients with advanced high-risk prostate cancer (PCa) are prone to have worse pathological diagnoses of positive surgical margins and/or lymph node invasion, resulting in early biochemical recurrence (BCR) despite having undergone radical prostatectomy (RP). Therefore, it is controversial whether patients with high-risk PCa should undergo RP. The purpose of this study was to evaluate the efficacy of neoadjuvant chemohormonal therapy (NAC) followed by “extended” RP. Methods A total of 87 patients with high-risk PCa prospectively underwent extended RP after NAC; most of the patients underwent 6 months of estramustine phosphate (EMP) 140 mg twice daily, along with a luteinizing hormone-releasing hormone agonist/antagonist. We developed our surgical technique to reduce the rate of positive surgical margins. We aimed to approach the muscle layer of the rectum by dissecting the mesorectal fascia and continuing the dissection through the mesorectum until the muscle layer of the rectum was exposed. Results More than 1 year had elapsed after surgery in all 86 patients, with a median follow-up period of 37.7 months. The 3-year BCR-free survival was 74.9%. Multivariate Cox-regression analysis revealed that a positive core ratio of 50% or greater and pathological stage of pT3 or greater were independent predictors for BCR. About 17 of 23 cases received salvage androgen deprivation therapy and concurrent external beam radiotherapy, and showed no progression after the salvage therapies. Conclusions NAC concordant with extended RP is feasible and might provide good cancer control for patients with high-risk PCa.


Urology ◽  
1997 ◽  
Vol 49 (3) ◽  
pp. 70-73 ◽  
Author(s):  
David G. McLeod ◽  
Charles F. Johnson ◽  
Eric Klein ◽  
James O. Peabody ◽  
Scott Coffield ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document